Advertisement

Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus

Published:December 06, 2010DOI:https://doi.org/10.1016/j.diabres.2010.10.018

      Abstract

      A randomized, placebo-controlled study evaluated the effects multiple-doses (28 days) dipeptidyl peptidase-IV (DPP-IV) inhibitor PF-734200 on DPP-IV activity, glucose, glucagon-like peptide-1 (GLP-1), glucagon and insulin levels in 72 subjects with type 2 diabetes. The relationship between changes in active GLP-1 and glucose during a meal test appeared non-linear.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ammirati M.J.
        • Andrews K.M.
        • Boyer D.D.
        • Brodeur A.M.
        • Danley D.E.
        • Doran S.D.
        • et al.
        (3,3-Difluoro-pyrrolidin-1-Yl)-[(2 s 4 s)-(4-(4-pyrimidin-2-Yl-piperazin-1-Yl)-pyrrolidin-2-Yl)]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
        Bioorg Med Chem Lett. 2009; 19: 1991-1995
        • Dai H.
        • Gustavson S.M.
        • Preston G.M.
        • Eskra J.D.
        • Calle R.
        • Hirshberg B.
        Non-linear increase in Glp-1 levels in response to Dpp-IV inhibition in healthy adult subjects.
        Diabetes Obes Metab. 2008; 10: 506-513
        • Mari A.
        • Sallas W.M.
        • He Y.L.
        • Watson C.
        • Ligueros-Saylan M.
        • Dunning B.E.
        • et al.
        Dipeptidyl peptidase-IV inhibitor improves model-assessed beta-cell function in patients with type 2 diabetes.
        J Clin Endocrinol Metab. 2005; 90: 4888-4894
        • Herman G.A.
        • Bergman A.
        • Stevens C.
        • Kotey P.
        • Yi B.
        • Zhao P.
        • et al.
        Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
        J Clin Endocrinol Metab. 2006; 91: 4612-4619
        • Utzschneider K.M.
        • Tong J.
        • Montgomery B.
        • Udayasankar J.
        • Gerchman F.
        • Marcovina S.M.
        • et al.
        The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
        Diabetes Care. 2008; 31: 108-113